Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 17995-17996 [2017-07595]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 71 / Friday, April 14, 2017 / Notices
FOR FURTHER INFORMATION CONTACT:
Theresa Kingsberry, Program Support
Specialist, Federal Trade Commission
Premerger Notification Office, Bureau of
Competition, Room CC–5301,
Washington, DC 20024, (202) 326–3100.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2017–07541 Filed 4–13–17; 8:45 am]
BILLING CODE 6750–01–P
GULF COAST ECOSYSTEM
RESTORATION COUNCIL
[Docket Number: 104142017–1111–11]
Notice of Proposed Subaward Under a
Council-Selected Restoration
Component Award
Gulf Coast Ecosystem
Restoration Council.
ACTION: Notice; correction.
AGENCY:
Committees the name of the recipient
and subrecipient; a brief description of
the activity, including its purpose; and
the amount of the award.
In the Federal Register notice of
March 14, 2017, at 82 FR 13607, the
Council provided notice of a proposed
subaward from NOAA to GOMA for the
purpose of supporting CMAP in
accordance with the Council Monitoring
& Assessment Program Development
award; however, the March 14, 2017
notice inadvertently omitted the amount
of the proposed subaward to GOMA.
The amount of the proposed subaward
from NOAA to GOMA under the
Council Monitoring & Assessment
Program Development award is
$525,000.
Will D. Spoon,
Program Analyst, Gulf Coast Ecosystem
Restoration Council.
[FR Doc. 2017–07562 Filed 4–13–17; 8:45 am]
BILLING CODE 6560–58–P
The Gulf Coast Ecosystem
Restoration Council (Council) published
a document in the Federal Register on
March 14, 2017 to provide notice of a
proposed subaward from the National
Oceanic and Atmospheric
Administration (NOAA) to the Gulf of
Mexico Alliance (GOMA), a nonprofit
organization, for the purpose of
supporting the Council Monitoring and
Assessment Program (CMAP) in
accordance with the Council Monitoring
& Assessment Program Development
award as approved in the Initial Funded
Priority List. The March 14, 2017 notice
did not include the amount of the
proposed subaward. Through this
correction, the Council publishes the
amount of the proposed subaward.
FOR FURTHER INFORMATION CONTACT:
Please send questions by email to
raams_pgmsupport@restorethegulf.gov.
SUPPLEMENTARY INFORMATION: Section
1321(t)(2)(E)(ii)(III) of the RESTORE Act
(33 U.S.C. 1321(t)(2)(E)(ii)(III)) and
Treasury’s implementing regulation at
31 CFR 34.401(b) require that, for
purposes of awards made under the
Council-Selected Restoration
Component, a State or Federal award
recipient may make a grant or subaward
to or enter into a cooperative agreement
with a nongovernmental entity that
equals or exceeds 10 percent of the total
amount of the award provided to the
State or Federal award recipient only if
certain notice requirements are met.
Specifically, at least 30 days before the
State or Federal award recipient enters
into such an agreement, the Council
must publish in the Federal Register
and deliver to specified Congressional
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:21 Apr 13, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2015–0020; Docket Number NIOSH
156–A]
Issuance of Final Guidance
Publications
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of issuance of final
guidance publications.
AGENCY:
NIOSH announces the
availability of the following final 14
IDLH Value Profiles: Iron
Pentacarbonyl, Acrylonitrile, 1,1Dichloro-1-Fluoroethane (HCFC–141b),
Chloroacetyl Chloride, Chlorine
Pentafluoride, Furan,
Hexafluoroacetone, n-Butyl Acrylate,
Benzontrile, Methyl Isocyanate,
Bromine Pentafluoride, 1,3-Butadiene,
Diketene and Butane.
DATES: The final IDLH documents were
published on October 5 and December
16, 2016.
ADDRESSES: These documents may be
obtained at the following links:
• Iron Pentacarbonyl: https://
www.cdc.gov/niosh/docs/2016-166/
• Acrylonitrile: https://www.cdc.gov/
niosh/docs/2016-167/
SUMMARY:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
17995
• 1,1-Dichloro-1-Fluoroethane (HCFC–
141b): https://www.cdc.gov/niosh/
docs/2016-168/
• Chloroacetyl Chloride: https://
www.cdc.gov/niosh/docs/2016-169/
• Chlorine Pentafluoride: https://
www.cdc.gov/niosh/docs/2016-170/
• Furan: https://www.cdc.gov/niosh/
docs/2016-171/
• Hexafluoroacetone: https://
www.cdc.gov/niosh/docs/2016-172/
• n-Butyl Acrylate: https://
www.cdc.gov/niosh/docs/2016-173/
• Butane: https://www.cdc.gov/niosh/
docs/2016-174/
• Benzontrile: https://www.cdc.gov/
niosh/docs/2017-104/
• Methyl Isocynate: https://
www.cdc.gov/niosh/docs/2017-105/
• Bromine Pentafluoride: https://
www.cdc.gov/niosh/docs/2017-106/
• 1,3-Butadiene: https://www.cdc.gov/
niosh/docs/2017-107/
• Diketene: https://www.cdc.gov/niosh/
docs/2017-108/
FOR FURTHER INFORMATION CONTACT: G.
Scott Dotson, NIOSH/Education and
Information Division, 1090 Tusculum
Ave., MS C–32, Cincinnati, OH 45226,
email address: fya8@cdc.gov.
SUPPLEMENTARY INFORMATION: On May 1,
2015, NIOSH published a request for
public review in the Federal Register
[80 FR 24930] on immediately
dangerous to life and health (IDLH)
values and support technical
documents. All comments received
were reviewed and accepted where
appropriate.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2017–07523 Filed 4–13–17; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcement (FOA)
GH17–002, Program Development and
Research to Establish and Evaluate
Innovative and Emerging Best Practices
in Clinical and Community Services
through the Presidents Emergency Plan
for AIDS Relief (PEPFAR); GH17–003,
E:\FR\FM\14APN1.SGM
14APN1
17996
Federal Register / Vol. 82, No. 71 / Friday, April 14, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
Conducting Public Health Research in
South Africa; GH17–004, Conducting
Public Health Research Activities in
Egypt.
Summary: This publication corrects a
notice that was published in the Federal
Register on April 4, 2017, Volume 82,
Number 63, page 16403. The meeting
announcement, meeting date, and
matters for discussion should read as
follows:
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcements GH17–
002, Program Development and
Research to Establish and Evaluate
Innovative and Emerging Best Practices
in Clinical and Community Services
through the President’s Emergency Plan
for AIDS Relief (PEPFAR); and GH17–
003, Conducting Public Health Research
in South Africa.
Time and Date: 9:00 a.m.–2:00 p.m.,
EDT, April 25, 2017, Panel A (Closed).
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Program Development and Research to
Establish and Evaluate Innovative and
Emerging Best Practices in Clinical and
Community Services through the
President’s Emergency Plan for AIDS
Relief (PEPFAR)’’, FOA GH17–002; and
‘‘Conducting Public Health Research in
South Africa’’, FOA GH17–003.
For Further Information Contact:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road
NE., Mailstop D–69, Atlanta, Georgia
30033, Telephone: (404) 639–4796,
HSHOOB@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–07595 Filed 4–13–17; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
16:21 Apr 13, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Health Resources and Services
Administration
CDC/HRSA Advisory Committee on
HIV, Viral Hepatitis and STD Prevention
and Treatment
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) and the
Health Resources and Services
Administration (HRSA) announce the
following committee meeting.
Times and Dates: 8:30 a.m.–5:00 p.m.,
EDT, May 10, 2017; 8:30 a.m.–3:00 p.m.,
EDT, May 11, 2017.
Place: CDC Corporate Square,
Building 8, Conference Room 1–ABC, 8
Corporate Boulevard, Atlanta, Georgia
30329, Telephone: (404) 639–8317. The
meeting is also accessible by
teleconference. Toll-free number 1–877–
603–4228, Participant code: 42598858.
Status: Open to the public, limited
only by the space available. The meeting
room will accommodate approximately
100 people. Persons who desire to make
an oral statement, may request it at the
time of the public comment period on
May 10, 2017 at 4:30 p.m., EDT. Public
participation and ability to comment
will be limited to space and time as it
permits.
Purpose: This committee is charged
with advising the Director, CDC and the
Administrator, HRSA, regarding
activities related to prevention and
control of HIV/AIDS, Viral Hepatitis and
other STDs, the support of health care
services to persons living with HIV/
AIDS, and education of health
professionals and the public about HIV/
AIDS, Viral Hepatitis and other STDs.
Matters for Discussion: Agenda items
include the following topics: (1) HIV
transmission risk in the context of viral
suppression and antiretroviral therapy
(ART) use; (2) Update on Pre-Exposure
Prophylaxis (PrEP) utilization; (3)
Vulnerable youth at risk for HIV, STDs,
hepatitis, substance use and other
health outcomes; (4) Eliminating
hepatitis B and hepatitis C as public
health threats in the United States—
Setting Goals and Taking Action; and (5)
Updates from Workgroups. Agenda
items are subject to change as priorities
dictate.
Contact Person for More Information:
Margie Scott-Cseh, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE., Mailstop E–07, Atlanta,
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Georgia 30329, telephone (404) 639–
8317; Email: zkr7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–07593 Filed 4–13–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC), National
Center for Emerging and Zoonotic
Infectious Diseases (NCEZID) announces
a meeting of the aforementioned
committee:
Time and Date: 1:00 p.m.–2:30 p.m.,
EDT, May 5, 2017.
Place: This meeting will be accessible
by teleconference. Toll-free +1 (888)
469–1070, Participant Code: 3132529.
Status: Open to the public limited
only by the availability of 200 telephone
ports. To register for this call, please go
to www.cdc.gov/hicpac.
Purpose: The Committee is charged
with providing advice and guidance to
the Director, Division of Healthcare
Quality Promotion, the Director,
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
the Director, CDC, the Secretary, Health
and Human Services regarding (1) the
practice of healthcare infection
prevention and control; (2) strategies for
surveillance, prevention, and control of
infections, antimicrobial resistance, and
related events in settings where
healthcare is provided; and (3) periodic
updating of CDC guidelines and other
policy statements regarding prevention
of healthcare-associated infections and
healthcare-related conditions.
Matters for Discussion: The agenda
will include a follow-up discussion on
the Draft Recommendation Update for
Chlorhexidine Impregnated Dressings.
Call materials will be made available to
the public no later than 2 business days
E:\FR\FM\14APN1.SGM
14APN1
]]>Agencies
[Federal Register Volume 82, Number 71 (Friday, April 14, 2017)]
[Notices]
[Pages 17995-17996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07595]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns the Centers for Disease
Control and Prevention (CDC) initial review of applications in response
to Funding Opportunity Announcement (FOA) GH17-002, Program Development
and Research to Establish and Evaluate Innovative and Emerging Best
Practices in Clinical and Community Services through the Presidents
Emergency Plan for AIDS Relief (PEPFAR); GH17-003,
[[Page 17996]]
Conducting Public Health Research in South Africa; GH17-004, Conducting
Public Health Research Activities in Egypt.
Summary: This publication corrects a notice that was published in
the Federal Register on April 4, 2017, Volume 82, Number 63, page
16403. The meeting announcement, meeting date, and matters for
discussion should read as follows:
The meeting announced below concerns the Centers for Disease
Control and Prevention (CDC) initial review of applications in response
to Funding Opportunity Announcements GH17-002, Program Development and
Research to Establish and Evaluate Innovative and Emerging Best
Practices in Clinical and Community Services through the President's
Emergency Plan for AIDS Relief (PEPFAR); and GH17-003, Conducting
Public Health Research in South Africa.
Time and Date: 9:00 a.m.-2:00 p.m., EDT, April 25, 2017, Panel A
(Closed).
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Program Development and Research to Establish and Evaluate
Innovative and Emerging Best Practices in Clinical and Community
Services through the President's Emergency Plan for AIDS Relief
(PEPFAR)'', FOA GH17-002; and ``Conducting Public Health Research in
South Africa'', FOA GH17-003.
For Further Information Contact: Hylan Shoob, Scientific Review
Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600
Clifton Road NE., Mailstop D-69, Atlanta, Georgia 30033, Telephone:
(404) 639-4796, HSHOOB@CDC.GOV.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-07595 Filed 4-13-17; 8:45 am]
BILLING CODE 4163-18-P
